At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 23, 2026 at 07:00 ET
Pyxis Oncology reported financial results for 2025 and provided a clinical update on its lead asset, micvotabart pelidotin (MICVO), in head and neck cancer. The company completed enrollment in its Phase 1 monotherapy dose expansion study and expects updated data mid-2026. Preliminary data showed strong response rates, but revenues declined year-over-year due to lower milestone and royalty income. The company has sufficient cash to fund operations into Q4 2026.
- Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in Q1 2026
- Preliminary monotherapy data: 46% ORR and 92% DCR in 13 efficacy-evaluable patients
- Combination with KEYTRUDA®: 71% ORR and 100% DCR in 7 patients
- Revenues decreased to $13.9M in 2025 from $16.1M in 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access